IL238174A0 - Combined treatment with Valasertiv - Google Patents

Combined treatment with Valasertiv

Info

Publication number
IL238174A0
IL238174A0 IL238174A IL23817415A IL238174A0 IL 238174 A0 IL238174 A0 IL 238174A0 IL 238174 A IL238174 A IL 238174A IL 23817415 A IL23817415 A IL 23817415A IL 238174 A0 IL238174 A0 IL 238174A0
Authority
IL
Israel
Prior art keywords
volasertib
combination therapy
therapy
combination
Prior art date
Application number
IL238174A
Other languages
English (en)
Hebrew (he)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL238174A0 publication Critical patent/IL238174A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
IL238174A 2012-11-30 2015-04-12 Combined treatment with Valasertiv IL238174A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12195162 2012-11-30
PCT/EP2013/074862 WO2014083058A1 (en) 2012-11-30 2013-11-27 Combination therapy with volasertib

Publications (1)

Publication Number Publication Date
IL238174A0 true IL238174A0 (en) 2015-05-31

Family

ID=47325907

Family Applications (1)

Application Number Title Priority Date Filing Date
IL238174A IL238174A0 (en) 2012-11-30 2015-04-12 Combined treatment with Valasertiv

Country Status (15)

Country Link
US (2) US20140154304A1 (enExample)
EP (1) EP2925343A1 (enExample)
JP (1) JP2016501208A (enExample)
KR (1) KR20150090091A (enExample)
CN (1) CN104812400A (enExample)
AU (1) AU2013351180A1 (enExample)
BR (1) BR112015011748A2 (enExample)
CA (1) CA2889787A1 (enExample)
CL (1) CL2015001258A1 (enExample)
EA (1) EA201500579A1 (enExample)
IL (1) IL238174A0 (enExample)
IN (1) IN2015DN03075A (enExample)
MX (1) MX2015006592A (enExample)
PH (1) PH12015501113A1 (enExample)
WO (1) WO2014083058A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9867831B2 (en) * 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104306336B (zh) * 2014-11-18 2016-08-24 河北天成药业股份有限公司 枸橼酸柔红霉素脂质体注射液的制备工艺
CA3219061A1 (en) * 2015-11-11 2017-05-18 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
WO2021242859A1 (en) * 2020-05-27 2021-12-02 Duke University Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy
CN116785296B (zh) * 2023-06-06 2025-09-05 河北渤腾医药技术有限公司 一种plk1的抑制剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076454A1 (de) 2003-02-26 2004-09-10 Boehringer Ingelheim Pharma Gmbh & Co Kg Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
WO2008074572A1 (en) * 2006-12-20 2008-06-26 Universitätsklinikum Hamburg-Eppendorf Use of tri-substituted glycerol compounds for the treatment of hematological malignancies
SI3300601T1 (sl) * 2007-02-16 2022-05-31 Rotalec Ip Holdings Llc Fiksna razmerja med zdravili za zdravljenje vrst hematopoetskega raka in proliferativnih motenj
US9358233B2 (en) * 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia

Also Published As

Publication number Publication date
KR20150090091A (ko) 2015-08-05
EA201500579A1 (ru) 2015-12-30
MX2015006592A (es) 2015-08-05
IN2015DN03075A (enExample) 2015-10-02
CN104812400A (zh) 2015-07-29
JP2016501208A (ja) 2016-01-18
US20170173023A1 (en) 2017-06-22
WO2014083058A1 (en) 2014-06-05
PH12015501113A1 (en) 2015-08-17
US20140154304A1 (en) 2014-06-05
AU2013351180A1 (en) 2015-04-30
CL2015001258A1 (es) 2015-10-02
EP2925343A1 (en) 2015-10-07
BR112015011748A2 (pt) 2017-07-11
CA2889787A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
ZA201305897B (en) Combination therapy
EP2934531A4 (en) COMBINATION
ZA201400120B (en) Combination therapy
GB201217439D0 (en) Combination therapy
LT3143972T (lt) Blauzdinio pėdos sąnario ortozė
PT2914254T (pt) Terapias de combinação para tratar cancros quimiorresistentes
EP2911673A4 (en) COMBINATION
EP2920142A4 (en) MÉTHANOFULLERRÈNES
GB201207305D0 (en) Therapy
EP2701744A4 (en) COMBINATION THERAPY
IL238174A0 (en) Combined treatment with Valasertiv
EP2879707A4 (en) COMBINATION THERAPY
EP2804853A4 (en) THERAPEUTIC USES
GB201203307D0 (en) Remvox
EP2925728A4 (en) COMBINATION
GB201211543D0 (en) Combination therapy
EP2908816A4 (en) ASSOCIATION
EP2908815A4 (en) COMBINATION
GB201210016D0 (en) Photodynamic therapy
GB201216178D0 (en) Combination
GB201114226D0 (en) Combination therapy
GB201206393D0 (en) Use
AU2012902291A0 (en) Combination Therapy
GB201221326D0 (en) Novel treatments
HU4212U (en) Safety base-paper with special paper-carrier